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Phenylephrine (PE) is the most commonly used over-the-counter nasal decongestant. The 
problem associated with phenylephrine is that it undergoes extensive first pass metabolism in 
the intestinal gut wall leading to its poor and variable oral bioavailability.  
This research project aims at developing strategies in order to increase the oral bioavailability 
of PE by co-administration of GRAS compounds. A HILIC assay method was developed to 
detect the parent drug, phenylephrine (PE) and its sulfate metabolite (PES).
 
The enzyme 
kinetic studies were done with phenolic dietary or GRAS compounds using LS180 human 
intestinal cell model, recombinant SULT enzymes and human intestinal cytosol (HIC). From 
the screening studies done, one inhibitor was selected in order to study the mechanism of 
inhibition. In conclusion the studies done in vitro provided a basis in order to predict in vivo 
intrinsic clearance through the sulfation pathway.
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1 Introduction 
1.1  Clinical significance of Phenylephrine 
Phenylephrine is the most commonly used over the counter (OTC) nasal decongestant. It acts 
on α1-adrenergic receptors, causes constriction of the blood vessels and prevents nasal 
decongestion and stuffy nose. The other available nasal decongestants that can be used are 
pseudoephedrine (brand name: Sudafed™), phenylpropanolamine and oxymetazoline. 
Pseudoephedrine is used as a precursor in manufacture of methamphetamine (1) and hence it 
is sold “behind the counter”. Although pseudoephedrine has higher bioavailability as 
compared to phenylephrine it acts on both α and β receptors and is non-specific in its mode of 
action. This leads to both vasoconstriction and increase in mucociliary clearance due to its 
nonspecific activity on adrenergic receptors. In the United States, the Food and Drug 
Administration (FDA) issued a public health advisory (2) against the use of 
phenylpropanolamine (PPA) in November 2000. In this advisory, the FDA requested that all 
drug companies discontinue marketing products containing PPA (3). The agency estimates 
that PPA caused between 200 and 500 strokes per year among 18-to-49-year-old users (3). In 
2005, the FDA removed PPA from over-the-counter sale (4). Because of its potential use 
in amphetamine manufacture, it is controlled by the Combat Methamphetamine Epidemic Act 
of 2005 (3). It is recommended that oxymetazoline should not be used for more than three 
days, as rebound congestion, or rhinitis medicamentosa, may occur (5). Because of these 
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reasons phenylephrine (Figure 1.1) is the most preferred alternative approach to treat nasal 
decongestion. 
                                         Figure 1.1 Structure of Phenylephrine (6) 
 
 
Table 1.1 Physicochemical properties of PE (7) 
 
Table 1.2 Pharmacokinetic properties of PE (7) 
     
Physicochemical Parameter Value 
Molecular Weight 167.0 g/mol 
Molecular Formula C9H13NO2 
Melting Point 140-145
°
C 
Solubility Freely soluble in Water 
LogP -0.31 
pKa (basic) 8.97 
Pharmacokinetic Parameter Value 
Bioavailability 38 ± 14% 
Tmax 1-1.3 hours 
Plasma Protein Binding 95% 
Volume of Distribution (Vdss) 340±174 liters 
Excretion 3% unchanged in urine  
(through IV route) 
t1/2 (half life) 2.1-3.4 hours 
 
 3 
1.2 Low and variable oral bioavailability of PE 
The problem associated with phenylephrine is that it undergoes extensive first pass 
metabolism in the intestinal gut wall leading to its poor and variable oral bioavailability. The 
metabolism pathways are influenced by route of administration. After oral ingestion, sulfate 
conjugation plays the most important role and the first pass metabolism (mainly conjugation 
within the gut-wall) decreases the amount of drug entering the systemic circulation to about 
40% of the dose (8). However after I.V injection deamination through MAO (monoamine 
oxidase) metabolism is the pre-dominant metabolic pathway and conjugation is of minor 
importance (8).  
Sulfated molecules are readily eliminated in bile and in urine. Sulfotransferases (also known 
as SULTs) are the super family of enzymes that catalyze the sulfate conjugation of various 
substrates such as xenobiotics, steroids, small endogenous substrates (neurotransmitters, bile 
acids etc). They are present in the aqueous cytosol and are called cytosolic proteins. 
SULT1A3 is the dominant SULT responsible for sulfation of PE (9). SULT1A3 shares seven 
out of ten aromatic residues in its substrate binding site with SULT1A1 but has much 
narrower specificity (10). The active site alters its own conformation to process molecules 
and it involves the enzyme automatically sensing the structural characteristics of the potential 
substrate and then molding itself around it (10). The co-factor involved in the sulfate 
conjugation reaction is PAPS (3’-phosphoadenosine-5’-phosphosulfate) which is the sulfate 
donor (Figure 1.2). Sulfate present in the body is loaded on ATP to form adenosine-5’-
phosphosulfate (APS) (11). This APS then reacts with another molecule of ATP to form the 
co-factor PAPS. PAPS then donates its sulfuryl group to the substrate in presence of SULTs 
to form the sulfate metabolite (11). Sulfation is generally a high affinity-low capacity 
pathway.   
 
 4 
 
 
Figure 1.2 Basic reaction for Sulfotransferases (11) 
 
A high dose of phenylephrine in order to increase the oral bioavailability of PE challenges the 
intestine with a very high concentration of a powerful α-adenoreceptor agonist (8). This 
would cause vasoconstriction of the intestinal blood vessels and prevent the transport of PE 
from the site of absorption to the systemic circulation (8). This research project aims at 
developing strategies in order to increase the oral bioavailability of PE by inhibiting the 
sulfation pathway. The inhibition of the sulfation pathway would help in increasing the 
bioavailability as well decrease the variability in fraction absorbed of PE. In order to achieve 
this goal it was essential to develop a bio-analytical method to detect the parent drug, 
phenylephrine (PE) and its sulfate metabolite phenylephrine-3-O-sulfate (PES).  
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1.3  Detection techniques to measure the metabolite 
There are techniques available for measuring the activity of the SULT enzyme like the 
radiometric technique, sulfatase assay and PAPS regeneration assay. In the radiometric 
detection technique, the assay utilizes [
35
S]PAPS and measures the formation of 
35
S-
conjugated substrates (12). Barium precipitation is utilized to remove the [
35
S]PAPS and free 
sulfate from the reaction mixture allowing determination of the unprecipitated 
35
S-products 
via scintillation counting (12). The problems associated with the use of barium precipitation 
assay are the sulfation of buffer components, substrate contaminants and tissue preparations 
as the assay does not distinguish between the sulfated products (12). The assay cannot 
distinguish between the sulfated products of PE and the inhibitors (GRAS or dietary 
compounds), thus confounding one of the goals of the present work. Also high backgrounds 
are generated with cytosol and cell lysate as certain SULTs are capable of sulfating free 
tyrosine leading to peptide sulfation (12). It also requires radiolabeled [
35
S] PAPS which is 
very expensive and highly regulated.  
Sulfatase assay involves use of sulfatases enzymes of the esterase class that catalyze the 
hydrolysis of sulfate esters. Sulfatases would cleave the sulfate metabolite and free the parent 
drug. But the drawback with this method is that the sulfate and phosphate esters have similar 
bond lengths and geometries and linear free energy relationships which suggest that their 
reactions in solution proceed via similar dissociative transition states (13) and hence are not 
completely selective.  For the PAPS regeneration assay, some methods may proceed to direct 
quantification of the sulfated metabolite (eg, 1-naphthyl sulfate, 4-methylumbelliferyl sulfate 
(4MUS), acetaminophen sulfate, p-nitro phenyl sulfate (PNPS), etc).  Others may use either 
4MUS or PNPS as the source of sulfate, then measure the fluorescence or absorbance of the 
liberated products (4-MU, 1-naphthol, PNP or APAP).  These would then be indirect ways to 
measure the rate of sulfation of a metabolite, by subtracting the baseline rate of 4MU or PNP 
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generation from the rate in the presence of the SULT substrate. One of the drawbacks with 
this method is that if the sulfation of the substrate is directly measured, we would be 
dependent upon one or more SULT isoforms to form PAPS from 4MUS or PNPS.  Thus we 
may have competition between the formation of PAPS (from 4MUS or PNPS) and the 
formation of the sulfated metabolite of interest.  
In order to overcome these shortcomings of these methods we attempted to develop an 
analytical method for direct detection of PES as well as help in simultaneous quantification of 
PE and PES. As PE and PES are highly hydrophilic compounds they were poorly retained on 
traditional RP-HPLC columns. Also there were matrix effects and unreliable chromatography 
issues seen with LC-MS/MS. Hydrophilic interaction liquid chromatography (HILIC) assay 
was used for direct detection of PES. It is an alternative assay method which encompasses 
certain aspects of reverse phase (RP-HPLC), normal phase HPLC and ion exchange 
chromatography. This technique is used for the separation of charged and hydrophilic 
compounds and involves a hydrophilic partitioning between the water enriched layer at the 
stationary phase and the less polar mobile phase. As PE and PES have conjugated ring 
structures fluorescence detection technique was used. 
1.4  Strategy to improve oral bioavailability of PE 
Efficacy of PE is questionable due to its low and variable bioavailability. This can be 
attributed to its extensive pre-systemic metabolism. If this pre-systemic metabolism is 
inhibited, bioavailability of PE can be improved. As mentioned earlier, more PE is 
conjugated mainly as sulfate by the oral route (45.7%) than that by the intravenous route 
(8.3%) (8). Less PE is bio-transformed to 3-hydroxymandelic acid by the oral route (24.2%) 
(8). This tells us that sulfation plays a major role in presystemic metabolism of PE. If the 
presystemic sulfation of PE can be inhibited, bioavailability of PE can be increased. The 
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preferred site for sulfation is the phenolic group, which is a common structural characteristic 
of many SULT substrate such as PE. Co-administration of phenolic GRAS (generally 
regarded as safe) and dietary compounds along with PE can be a suitable strategy to inhibit 
presystemic metabolism of PE. Several phenolic GRAS and dietary compounds were 
included in the study: eugenol, resveratrol, zingerone, isoeugenol, ethyl vanillin, quercetin, 
pterostilbene, propyl paraben, vanillin, raspberry ketone, curcumin, methyl paraben and 
magnolol. Many successful examples of applying dietary compounds to inhibit metabolism 
and finally to improve the oral bioavailability are found in the literature. Systemic exposure, 
metabolism, pharmacokinetics and toxicology are the aspects considered for safety of GRAS 
compounds and have been evaluated (14). Hence it is a safe strategy to include these phenolic 
GRAS compounds in the final formulation to inhibit presystemic metabolism of PE through 
sulfation. Since MAO inhibitors can cause hypertension, systemic MAO inhibition is not 
desired. The presented work involves the kinetic studies on inhibition of sulfation with 
phenolic compounds using recombinant SULT enzymes and human intestinal cytosol (HIC). 
The IC50 values of these compounds were determined in the human intestinal LS180 cell 
model and an attempt was made to determine the mechanism of inhibition in the HIC. 
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2 HPLC Method   
2.1  Introduction 
Methods are available for the determination of PE in pharmaceutical formulations by HPLC 
using ion-pair and hydrophilic interaction liquid chromatography (HILIC) coupled with 
fluorescence detection as described by Dousa et.al. (15). However these methods do not 
enable the simultaneous quantitation of the highly hydrophilic metabolite PES as well as PE 
in in vitro systems like LS180 cells, recombinant enzymes and human intestinal cytosol. The 
objective of the presented work was to develop a quick and sensitive quantitative 
chromatographic method with improved retention and separation of the hydrophilic PES and 
PE, having improved sensitivity, short run time and simultaneous detection of PE and its 
metabolite PES.  
The sulfation of PE occurs at its phenolic group to form phenylephrine 3-O-sulfate (PES), 
which is the preferred structural feature of many sulfotransferases substrates. Hence it is 
essential to have information about PES formation vs disappearance of PE in order to study 
the metabolism of PE. Due to the very low lipophilicity, high polar nature of PES and its 
zwitterionic character it is not retained on RP-HPLC and hence its separation and quantitation 
are very difficult. Secondly as the mass of PES is quite low, sensitive analytical method for 
determination of PES is needed. In our experience, LC-MS/MS was attempted to detect PES 
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but the ionization and sensitivity for PES were not good, due to the highly aqueous mobile 
phase.  Also, the chromatography was unreliable and matrix effect issues were seen.  
Hydrophilic interaction liquid chromatography (HILIC) has recently become more important, 
particularly for the analysis of polar drugs, metabolites and biologically relevant compounds 
in glycomics, proteomics, metabolomics and clinical analysis (16). It is an alternative strategy 
to ion-exchange and normal-phase liquid chromatography. HILIC is also used for analyzing a 
variety of ionizable compounds.  As it contains a greater portion of organic phase which has 
low viscosity, the generated back pressure is very low. This allows higher flow rates and 
smaller particle diameter size. As described in Figure 2.1, it can be regarded as a mix of 
reverse-phase LC (similar mobile phase, organic modifier and pH range), normal phase LC 
(similar stationary phase) and ion exchange chromatography (similar to type of compounds 
that can be analyzed). The retention mechanism of HILIC involves (i) hydrophilic 
partitioning between a water enriched layer at the stationary phase surface and comparatively 
less polar mobile phase (ii) ion-exchange between the charged analyte and the stationary 
phase (iii) adsorption of the analyte on the stationary phase due to hydrogen bonding [2]. As 
such it has overlapping characteristics with RP-HPLC, NP-LC and IC.      
                                                                                              
Figure 2.1 HILIC chromatography (17)  
  
NP-LC: Normal Phase liquid chromatography, IC: Ion-exchange chromatography, NP-LC: Normal 
phase liquid chromatography 
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The main advantage of HILIC is the ability to retain polar analytes without the need of toxic, 
flammable, and/or expensive solvents as used in normal phase chromatography. Hence a 
sensitive HILIC HPLC method was developed using a zwitterionic sulphoalkylbetaine 
column. It contains both sulphonic acid (anionic) and quaternary ammonium (cationic), 
separated by a short alkyl spacer.  
2.2 Method Development 
2.2.1 Experimental 
2.2.1.1 Chemicals and reagents 
L-phenylephrine hydrochloride (USP grade), phenylephrine sulfate, β-estradiol glucuronide, 
(E2-3G; internal standard), 50% w/v dextrose (USP grade, Butler Schein). Methanol 
(Honeywell, B & J ACS/HPLC certified Solvent), acetonitrile (Macron fine chemicals), 
triethylamine (Fischer Scientific, HPLC grade), formic acid (Fischer Chemicals, certified 
ACS) and ammonium hydroxide (BDH, ACS grade) were purchased. Water was filtered 
through the NANOpure Diamond Ultrapure Water system from Barnstead International 
(Dubuque, IA, USA). All other chemicals, solvents or reagents were of analytical grade and 
were obtained from Sigma-Aldrich (St Louis, MO) or Fisher Scientific unless indicated 
above. PES was synthesized in our lab. (Zhang et al.; manuscript in preparation) 
2.2.1.2 Instrumentation 
Separation of analytes was performed using an EC 100X4.6 mm Nucleodur HILIC, 3µm 
(Macherey – Nagel,) column preceded by a phenomenex HILIC Security Guard Cartridge. 
The HPLC system (Waters, Milford MA) consisted of the Alliance 2695 separations module 
and a 2475 fluorescence detector with excitation wavelength of 268 nm and emission 
wavelength of 293 nm. These wavelengths were obtained from maxima observed with 
fluorescent scan  obtained in the lab.  The fluorescent intensity of PE was almost 4 times 
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greater than the fluorescent intensity of PES, on an equimolar basis. Data were collected and 
analyzed using Waters Empower 2 or Empower 3 software. 
2.2.1.3 Chromatographic conditions 
Preparation of buffer for mobile phase: To 250 mL of HPLC grade water, 1250 µL of 
TEA and 780 µL of ammonium hydroxide was added. pH was adjusted to 4.5 with formic 
acid. 
Mobile phase A:  ACN: MeOH: Buffer (72: 8: 20). This was filtered through 0.45 µM 
Millipore filter after mixing.  
Mobile phase B: 100% ACN 
Determination of PE, PES and E2-3G was performed with isocratic elution (Mobile phase A: 
Mobile Phase B, 90:10) at a flow rate of 0.8 mL/min. The injection volume was 25 µL. The 
runtime was 6.0 mins. The column temperature was maintained at 30°C and the autosampler 
compartment was set to 4°C. PE and PES were detected at the excitation wavelength of 268 
nm and emission wavelength of 293 nm (as determined by fluorescence spectral scans of PE 
and PES in HPLC mobile phase) with retention times as follows: PES: 3.2 mins, PE : 4.3 
mins and E2-3G: 2.6 mins. This model is analytically convenient since PE and PES can be 
readily and simultaneously quantitated by using a fluorescent detection. Due to high 
selectivity and sensitivity, fluorescence detection is more suitable than UV detection at 275 
nm, as described in the current European Pharmacopeia and U.S Pharmacopeia (USP) 
methods (15). LS180 cell culture techniques were used as described in Chapter 3.  
The method was intended to be developed for application to LS180 cells, recombinant 
enzymes and human intestinal cytosol. The samples containing PE and PES in aqueous buffer 
could not be injected directly on the HILIC column as they had poor retention when injected 
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directly because water is a strong solvent in HILIC chromatography. The nature of the 
sample diluent is a major issue in HILIC and can lead to severe peak distortion especially 
when the sample diluent contains ≥ 40% water. PE and PES, being very hydrophilic 
compounds were difficult to extract with an organic solvent from aqueous media. Thus the 
samples were deproteinized with acetonitrile and ACN/water phase separation was achieved 
by “sugaring out” with 50% w/v dextrose. 
Conditioned DPBS was prepared by incubating confluent LS180 cells for 8 hours in DPBS 
followed by centrifugation for 5 mins at 4000 g at 25°C and stored at -20°C. The samples of 
the LS180 cells in conditioned DPBS buffer and ACN were mixed in the ratio of 1:4. The 
method involved the extraction of PE and PES in the ACN layer. Due to the use of an 
extraction technique in the sample preparation method it was necessary to include an internal 
standard in the method. For the selection of an internal standard, various Phase II small 
hydrophilic metabolites structurally similar to PE and PES were tested. The following 
compounds were tested as the internal standard for the method: 
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Table 2.1 List of compounds tested as internal standards 
Analyte tested 
Peak start 
(min) 
Peak ends 
(min) 
Peak shape 
etilephrine (ET) 3.3 3.75 Broad and slightly          distorted 
etilephrine sulfate (ETS) 3.75 4.15 Broad and overlapping with adjacent peak 
Tyrosol 3.80 4.20 Broad and overlapping with adjacent peak 
Tyramine 3.64 4.20 Broad 
Tyrosine 4.20 >5.0 Very broad and not completely eluted 
albuterol 3.54 4.20 Very broad peak shape 
1-naphthol 
pyridoxine 
1.35 
2.15 
1.9 
2.80 
Negative peak, poorly retained 
Broad peak shape 
dopamine 4.40 >5.0 Incomplete elution and broad peak shape 
4-methylumbeliferone sulfate 
4-methylumbeliferone 
2.55 
1.20 
2.95 
1.70 
Negative peak 
Peak seen in void 
4-nitrosophenyl beta-glucuronide 1.30 1.70 Peak seen in the solvent front 
beta estradiol - - Peak seen in the solvent front 
4-nitrophenyl sulfate 
beta estradiol glucuronide 
alpha-naphthyl sulfate                    
1.30 
2.00 
- 
1.60 
2.4 
- 
Peak seen in the solvent front and negative peak 
Good peak shape 
Peak seen in the solvent front 
ethynyl estradiol - - Peak seen in the solvent front  
ellagic acid 1.25 1.75 Peak seen in the solvent front 
acetaminophen glucuronide 3.85 4.22 Negative peak seen 
vanillic acid 2.20 3.00 Peak split 
fluorescein - - Peak seen in the solvent front 
Calcein 3.90 4.60 Broad peak shape 
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From the above studies 17 β-estradiol glucuronide (E2-3G) was selected as the internal 
standard for the method. E2-3G was also detected at the same excitation and emission 
wavelength with a retention time of 2.6 mins. 
2.2.2 Extraction Efficiency 
It was observed that complete extraction of PE and PES was not seen in the ACN layer. This 
further generated a need to have a phase separation method in order to increase the extraction 
efficiency of PE and PES in the ACN layer. First, “salting out” methods were attempted. 
Various combinations of salt solutions were used such as saturated solution of ammonium 
sulfate, saturated solution of ammonium sulfate (pH adjusted to 9.3 with ammonium 
hydroxide) and saturated solution of ammonium sulfate (pH adjusted to 9.3 with TEA). These 
salt solutions (4%) were added to the mixture of aqueous buffer: ACN (1:4). The extraction 
efficiency observed with the salting out method was less than 50% for both PE and PES. The 
next attempt to increase the extraction efficiency was using the “sugaring-out” method.  The 
“sugaring- out” method is a less commonly used phase separation method which uses sugar 
as a mass separating agent. The use of a monomeric sugar such as dextrose to an ACN-water 
mixture created two phases: one that is ACN rich (top) and an aqueous phase (bottom). The 
uncharged but polar biomolecules such as sugars dissolve readily in water because of the 
stabilizing effect of hydrogen bonds between the hydroxyl group of the sugar and the polar 
water molecules (18). It is likely that some original hydrogen bonds in the mixture between 
PE, PES with water are replaced by the hydrogen bonds formed between sugar and water 
molecules which may force ACN molecules to separate from water molecules and form a 
separate phase. Sugaring out of the sample provides an advantage over the salting out 
technique as it does not alter pH as compared to the salting out technique. Also salting out 
happens at high concentrations of salt which leads to distorted peak shapes in HILIC 
chromatography.  In this study, we tested several sugars including meso-erythritol, 
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maltodextrin, dextran sulfate, sucrose, sucralose, and dextrose (D-glucose), and chose 
dextrose for further studies since it appeared to give the highest recovery and minimal 
chromatographic interference. 
After extraction, the large volume of ACN needed to be reduced. PE was found to be unstable 
during evaporation under a stream of nitrogen gas at 55°C using a Turbo-Vap, consistent with 
the previously published literature (19, 20) . Hence vacuum evaporation was employed in 
order to evaporate the ACN layer in order to concentrate the analytes, followed by 
reconstitution with mobile phase. These processes are described below. 
2.2.3 Preparation of assay standard and QC samples 
Conditioned DPBS was prepared by exposing DPBS (calcium chloride 100 mg/L, 
magnesium chloride 100 mg/mL, potassium chloride 200 mg/mL, potassium phosphate 
monobasic 200 mg/L, sodium chloride 8g/L, sodium phosphate dibasic 2.16 g/L, D-glucose 
1g/L and sodium pyruvate 36mg/L in water, pH 7.4) to confluent LS180 cells for 8 hours 
followed by centrifugation for 5 mins at 4000 g at 25°C and stored at -20°C. Standard 
samples of 250 µL PE (200, 50, 5, 12.5, 3.13, 1.56, 0.781 and 0.390 µM) and standard 
samples of 250 µL PES (32, 8, 4, 2, 2.5, 0.5, 0.25, 0.125 and 0.0625 µM) in conditioned 
DPBS buffer were prepared. To the standard samples 1000 µL of ACN containing 24 µM of 
E2-3G was added. Dextrose solution (50%w/v) 62.5 µL was added for phase separation. The 
standards were vortexed for 30 seconds and then centrifuged for 5 mins at 4000g at room 
temperature. The ACN layer (1000 µL) was decanted and retained. Another 1000 µL ACN 
without the internal standard was added and the standard samples were again vortexed and 
centrifuged as above. ACN layers from both the extractions were pooled and evaporated 
using the Speed Vac (Savant Instrument Corp., Farmingdale, NY) under reduced pressure. 
The standard samples were then reconstituted with 200 µL of mobile phase (A:B = 9:1) and 
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then injected into HPLC system using the chromatographic conditions described above. 
Quality control (QC) samples containing PE (100, 6.25 and 0.39 µM) and PES (16, 1 and 
0.0625 µM) were independently prepared in the same manner. Twenty-five microliters of the 
standard or QC sample was injected into the HPLC for quantitation. 
The extraction efficiency of the analytes (PE and PES) and internal standard (E2-3G) into the 
ACN layer was checked. Minimum of two extractions were necessary to maximize the 
extraction of PE, PES and E2-3G. The extraction efficiency of the analytes were checked at 
low, medium and high concentrations of the analytes. For this study, the peak area ratios of 
the analyte and the internal standard of the spiked QC samples after two extractions and the 
analytes spiked in the mobile phase were compared, as shown in Table 2.2. 
Table 2.2 Percent Extraction efficiency (mean ± S.D; %C.V) for the determination of 
the analytes as compared to unextracted Standards 
Level PE PES  E2-3G 
QC 1 65.6 ± 1.1 
(1.66%) 
52.5 ± 1.0 
(1.96%) 
 32.7 ± 0.2 
(0.55%) 
QC 2 62.5 ± 2.2 
(3.44%) 
50.5 ± 1.7 
(3.34%) 
 33.6 ± 0.7 
(2.14%) 
QC 3 54.3 ± 2.2 
(4.09%) 
48.9 ± 1.6 
(3.23%) 
 37.2 ± 0.8 
(2.15%) 
 
The observed absolute extraction efficiency was low but the standard deviation was low and 
the consistency was high. Although at least 70% of the extraction efficiency is preferred but 
this was acceptable because the reproducibility and the consistency was high, demonstrated 
by very low relative standard deviation values (all < 5%)  
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2.3 Validation  
The validation study was performed as per the FDA bioanalytical guidelines for assay 
validation. 
2.3.1 Specificity  
The assay method was found to be specific for PE, PES and E2-3G when compared with 
blank. Blank was extracted in the same way as the samples with conditioned DPBS buffer 
and without PE, PES and E2-3G.  
2.3.2 Linearity and LLOQ  
Eight calibration standards with concentrations (200, 50, 25, 12.5, 3.12, 1.56, 0.78 and 0.39 
µM for PE) and (32, 8, 4, 2, 2.5, 0.5, 0.25, 0.125 and 0.0625 µM for PES) were extracted in 
duplicate and analyzed in three independent runs. Calibration curves were fitted using the 
linear regression of the ratio of the peak area response of the analyte and the internal standard 
versus concentration. For each calibration curve, the back-calculated concentrations were 
required to be within ±15% of nominal concentration (DFN) except at the limit of 
quantification (LLOQ) where it was within ± 20%. 
Table 2.3 Assay parameters for determination of analytes 
Analyte Concentration 
Range (µM) 
Retention 
time
a
 
(min) 
 LLOQ (µM) Regression 
coefficient
b
 
PE 0.39-200 4.4±0.055  0.39 0.9997-1.0000 
PES 0.063-32 3.2±0.039  0.063 0.9999-1.0000 
E2-3G 
(internal standard) 
24.0 2.7±0.029  - - 
    LLOQ, Lower limit of quantification; sample volume 25µL 
         a 
Mean ± S.D. for four replicates.             
 b 
Range   
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2.3.3 Accuracy and Precision:  
The intraday accuracy and precision were evaluated by assaying three replicates of the QC 
samples each in two analytical runs on the same day. The interday accuracy and precision 
were evaluated by assaying three replicates of the QC samples each in analytical runs on 3 
different days. Precision was characterized by the coefficient of variance (CV, %) whereas 
accuracy was expressed as deviation from the nominal value (DFN, %) as shown in Tables 
2.4, 2.5, 2.6 and 2.7.  
 
Table 2.4 Assay validation results for determination of analytes 
Analyte 
(PES) 
Nominal Concentration 
(µM) 
               Intraday (n = 6) 
   Measured  
concentration      Accuracy         Precision                                                                         
     (µM)                DFN (%)           CV (%)                         
 
 
LLOQ 0.063 0.057 ± 0.0064         9.0                 11  
QC1 1   0.91 ± 0.020           8.7                 2.2  
QC2 16      16 ± 0.29             2.4                 2.0  
QC3 24      24 ± 0.20             0.3                0.79  
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Table 2.5 Assay validation results for determination of analytes 
Analyte 
(PE) 
Nominal Concentration 
(µM) 
               Intraday (n = 6) 
   Measured  
concentration      Accuracy         Precision                                                                         
     (µM)                DFN (%)           CV (%)                         
 
LLOQ 0.39 0.46 ± 0.013             16                     3.0 
QC1 6.25 6.4 ± 0.20                 3.1                    2.8 
QC2 100 103 ± 2                     2.6                    2.3 
QC3 150 150 ± 1                    0.01                  0.53 
 
Table 2.6  Assay validation results for determination of analytes 
Analyte 
(PES) 
Nominal Concentration 
(µM) 
               Interday (n = 9) 
  Measured  
concentration      Accuracy         Precision                                                                         
     (µM)                DFN (%)           CV (%)                         
 
LLOQ 0.063 0.056±0.0071            9.0                  11 
QC1 1.0                    0.95±0.065                4.6                  6.9 
QC2 16.0 16±0.30                     2.6                  1.8 
QC3 24.0 24±0.60                     1.1                  2.4 
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Table 2.7 Assay validation results for determination of analytes 
Analyte 
(PE) 
Nominal Concentration 
(µM) 
               Interday (n = 9) 
   Measured  
concentration      Accuracy         Precision                                                                         
     (µM)                DFN (%)           CV (%)                         
LLOQ 0.391 0.45±0.039              8.6                     16 
QC1 6.25   6.6±0.25                3.8                   -5.3 
QC2 100   104±3                    3.2                   -4.3 
QC3 150   154±6                    3.8                   -2.5 
 
2.3.4 Post processing stability:  
The stability of the standard and spiked QC samples at the working level concentration (50 
µM for PE) were determined for 18.5 hours within the injector port in order to demonstrate 
good stability of processed samples to facilitate long analytical sample runs. The analytes 
were quantified at 0 and 18.5 hours to compare the ratio of the peak areas of the analyte and 
the internal standard at time 0 with the ratio of the peak area of the analyte and the internal 
standard at 18.5 hours. These data are reported in Tables 2.8 and 2.9. 
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Table 2.8 Post processing storage stability (injector port stability) 
PES Nominal concentration 
(μM) 
 
% PES Stability 
as compared to 
time 0 (mean ± 
S.D) 
 
QC 1 1 101 ± 4.0  
QC 2 16 100± 0.70  
QC 3 24 94 ± 0.52  
 
 
Table 2.9 Post processing storage stability (injector port stability) 
PE Nominal concentration 
(μM) 
 
% PE Stability 
as compared to 
time 0 (mean ± 
S.D) 
 
QC 1 6.25 103 ± 7  
QC 2 100 98 ± 2  
QC 3 150 94 ± 3  
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2.3.5 Results for validation  
The retention time, LLOQ and regression coefficients for the analysis of PE and PES for n = 
4 analytical runs are summarized in Table 2.3. The intraday and interday results for accuracy 
and precision at the LLOQ and the QC concentrations are presented in Tables 2.4, 2.5, 2.6 
and 2.7 For the QC samples, both interday and intraday accuracy showed less than 15.70 % 
DFN and the precision was within 12.81% CV, for PE as well as PES. There was a good 
linear relationship (1/Y
2
 weighted) between ratio of peak areas of the analytes and E2-3G and 
concentration (x) over the concentration range of 0.39 – 200 μM for PE and 0.0625 μM – 32 
μM for PES with linear regression yielding y = (0.1331 ± 0.0006)x – (0.000491 ± 0.000057) 
for PES and y = (0.1555 ± 0.0064) x+ (0.00547 ± 0.00652) for PE. The method was found to 
be specific, linear, precise and accurate. The present method was applied to study the 
saturation of PES formation using the LS180 human intestinal cell model (HIC), recombinant 
SULT1A3 enzyme and human intestinal cytosol. In this study a broad substrate (PE) 
concentration range was used from 1 µM – 3000 µM for LS180 intestinal cells and 3.125 µM 
– 200 µM for recombinant enzyme and HIC.  These data are presented in the subsequent 
chapters. 
2.4 Discussion  
The fluorescent spectra of PE and PES in HILIC mobile phase which is ACN rich was 
compared to RP-HPLC mobile phase which has high percent of aqueous content were 
compared. The fluorescent intensity of PE and PES in HILIC mobile phase was almost 2-fold 
higher as compared to RP-HPLC mobile phase. A HILIC assay method was developed and 
validated as the US-FDA guidelines for bioanalytical validation. The method was found to be 
specific, linear, accurate, precise and stable with a short run time. The developed method 
allowed direct quantification of PES with a LLOQ of 63 nM and had several advantages over 
the indirect methods used to determine PES. Although the absolute extraction efficiency was 
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low for the analytes, the % C.V was low (< 4%) and hence extraction was precise, 
reproducible and consistent. The developed method was convenient to use but at the same 
time its development was challenging with regards to analyte retention and separation, phase 
separation, and the sample preparation techniques. It was also envisioned to adapt the 
developed method in order to analyze PE and PES in plasma samples. 
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3 LS180 cell-based assays 
3.1 Introduction and objectives 
The LS180 is a human colon adenocarcinoma epithelial cell line. The LS180 cell line was 
used as a potential model to investigate the sulfation of PE. Cell lines are used as a screening 
tool in order to investigate drug metabolism. Sulfation activity of acetaminophen (which has 
a phenolic moiety) is observed with the LS180 cell line. Acetaminophen sulfation does not 
occur in the Caco-2 cells grown in a flask due to incomplete differentiation (21). Cell 
differentiation is necessary for Caco-2 cell in order to express SULT enzymes (8). The major 
limitations of the Caco-2 cell line are long term culturing time (3-4 weeks) and low 
expression of drug metabolizing enzymes. Although the in situ human intestinal perfusion 
studies gives a closer depiction on the physiological level, it suffers from several 
disadvantages such as complicated technology, short term viability and lack of tissue 
availability. The main aim behind this cell-based studies was to check the ability of the 
phenolic GRAS compounds to cross the intestinal cell membrane and reach the SULT 
enzyme in order to achieve the desired inhibition. The Km value observed for PE sulfation 
was used to decide upon the substrate concentration to be used for further studies. 
The objective of the presented work was to test the feasibility of using phenolic GRAS 
compounds to inhibit the PES formation and hence to increase the bioavailability of PE. In 
order to test this hypothesis in vitro LS180 cell model was used. The specific aims included 
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(i) Determine time and concentration dependent PES formation in LS180 cell model. (ii) 
Determine the enzyme kinetic parameters (Km and Vmax) using PE as the substrate. (iii) 
Determine the IC50 value for each GRAS compound used as an inhibitor for PES formation. 
(iv) Investigate whether the unknown metabolite seen in the chromatographic method is an 
MAO metabolite. 
It was also observed that as the dose of the PE is increased there was depletion of PAPS and 
the formation of the sulfate metabolite is decreased. 
3.2 LS180 Cell Culture (14) 
LS180 cells were grown in DMEM with high glucose (4.5 g/L), 10% FBS, and 1% non-
essential amino acid at 37 
o
C with 5% CO2. The cells were fed every other day. The cell 
culture medium was continuously increased from 12 to 25 mL in 75 cm
2
 flask to keep pace 
with increasing metabolic demands of the growing cells. When LS180 cells were sub-
cultured, old medium was removed and the 75 cm
2
 flask was filled with 5 mL fresh medium. 
Since trypsin changes the cell type, it was not used for cell sub-culture. Instead, cells were 
gently scraped by a cell scraper. In order to disperse the cells, cells were passed through a 
23G ×1 needle for 6 cycles and dispensed to a new flask. Cells were sub-cultured for 6-7 days 
with a dilution of 1:10. Cell passage number was between 42 and 60. A new vial of LS180 
cells was recovered from the liquid nitrogen about every 3 months. LS180 cells were seeded 
at a concentration of 1.9 x 10
5
 cells/mL in the 24 well plate (14). The experiment was carried 
out on the 4
th
 day after plating the cells (14).  
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3.3 Optimization experiments 
The HILIC assay method developed was used in order to study the PES formation. In order to 
study the PES formation it was important to determine the linearity of the PES formation 
with respect to time and substrate concentration of PE. 
3.3.1 Time course study 
In order to optimize the incubation time, the cells were incubated with DPBS buffer (calcium 
chloride 100 mg/L, magnesium chloride 100 mg/mL, potassium chloride 200 mg/mL, 
potassium phosphate monobasic 200 mg/L, sodium chloride 8g/L, sodium phosphate dibasic 
2.16 g/L, D-glucose 1g/L and sodium pyruvate 36mg/L in water, pH 7.4). To each well of a 
24-well plate 0.25 mL of start solution was added to each well. Time course study was done 
at 10 μM and 100 μM of PE in triplicates. The study was done up to 8 hours at 37°C in air 
incubator. The metabolic reactions were stopped using 1.0 mL ACN containing 24 μM E2-
3G as the internal standard. Dextrose (50% w/v) was used for phase separation. Double 
extraction was done in order to increase the extraction efficiency and the second extraction 
was done using 1.0 mL ACN without E2-3G. The ACN layers from both the extractions were 
pooled and evaporated using a SpeedVac (Savant). The samples were then reconstituted with 
the 200 μL of mobile phase and injected into the HPLC as previously described.   
3.3.1.1 Results 
The results are shown below in Figures 3.1 to 3.4 and Table 3.1. 
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Figure 3.1 Disappearance of PE at 10 μM over 8 hours 
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Figure 3.2 Formation of PES at PE (10 μM) over 8 hours 
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  Figure 3.3 Disappearance of PE at 100 μM over 8 hours 
 
Figure 3.4 Formation of PES at PE (100 μM) over 8 hours 
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When PE (10 μM and 100 μM) was incubated with LS180 cells for 8 hours it was 
progressively sulfated over 8 hours (shown in Figures 3.2 and 3.4). The formation of PES and 
disappearance of PE were linear up to 8 hours with the following linear regression estimates: 
Table 3.1 Linear regression estimates for the time course study   
 R
2
 Slope (± S.D) 
(pmoles/hr) 
At PE (10 μM)   
Disappearance of PE                     0.9215 -176 ± 16  
Appearance of PES                     0.9639    45 ± 1.7 
At PE (100 μM)   
Disappearance of PE 0.8721  -931 ± 113 
Appearance of PES 0.9842 95 ± 2.5 
 
This study tells us about the linear range of the time course. It was observed that over 8 hours 
at 10 μM PE, the disappearance rate of PE was almost 4 times greater as compared to 
formation rate of PES. Furthermore at 100 µM PE, the disappearance rate of PE was almost 
10 times greater as compared to formation rate of PES. Thus some other metabolism pathway 
apart from sulfation is also accountable for disappearance of PE using the LS180 cell model. 
Also from the data obtained, it was observed that as the concentration of the substrate is 
increased, the contribution of the sulfation pathway to total disappearance of PE becomes 
lesser and lesser. Thus PES formation appears saturable (or the cofactor PAPS may be 
depleted) within this range and another less saturable metabolic pathway contributes at higher 
concentrations of PE. Hence sulfation of PE appears to be a high affinity low capacity 
pathway 
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3.3.2 PES formation saturation study 
In order to optimize the substrate concentration to be used for further studies, the cells were 
incubated with DPBS buffer (already defined earlier in the chapter). To each well 0.25 mL of 
start solution was added containing PE covering a wide concentration range of (1-3000 µM) 
for 8 hours (from incubation time optimization study) at 37°C in an air incubator. At the end 
of 8 hours, the metabolic reactions were stopped using 1.0 mL ACN containing 24 μM E2-
3G as the internal standard. The samples at each concentration were prepared in triplicate and 
assayed by HPLC as previously described. 
3.3.2.1 Results 
Non-linear regression model was used to fit the data using Graph Pad Prism v5 software 
(GraphPad Inc., San Diego, CA). It was observed that the formation of PES is a saturable 
process at higher concentrations of PE as shown in Figures 3.5 and 3.6. It was also observed 
that the Hill model gave a better fit to the data as compared to the Michaelis-Menten model 
with p-value < 0.05 (for F-test). F-test takes into account the variances and the number of 
parameter estimates for different models. The Hill model was chosen to fit the data as shown 
in Table 3.2.  
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Figure 3.5 Formation of PES on a linear scale 
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Figure 3.6 Formation of PES on a semi-log scale 
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Table 3.2 Enzyme kinetic parameters using LS180 cell model  
 
 
 
 
The negative Hill co-efficient with the Hill model could be due to the lack of sulfur in the 
DPBS buffer. The system was falling short of sulfur as sulfur is required for the formation of 
PAPS. This effect was more prominent at higher concentrations of PE as PES formation was 
decreased and the curve shifted towards the right and its slope decreased giving rise to 
negative Hill co-efficient. There was a possibility that Hill co-efficient could have been 1.0 if 
the system had sufficient sulfur for the formation of PAPS. 
The Km value observed with this experiment for PE sulfation was used to decide upon the 
substrate concentration to be used for inhibition study of PES formation with the use of 
phenolic GRAS or dietary compounds. 
3.3.3  Inhibition of PES formation using Phenolic GRAS compounds 
The efficacy of PE has been questionable due to its low and variable bioavailability. This can 
be attributed to the extensive pre-systemic metabolism of PE. Employing strategies to inhibit 
the metabolism of PE can increase the oral bioavailability of PE. PE undergoes sulfate 
conjugation to form the sulfate metabolite PES, which is the major metabolite (45.7%) when 
given orally. Less PE is biotransformed to 3-hydroxymandelic acid by the oral route (24.2%) 
as compared to I.V route (56.9%) [2]. This tells us that sulfation is the major metabolic route 
in vivo when PE is given orally. Sulfation of PE occurs at its phenolic group which is a 
common feature of the SULT1 substrates. Prodrugs can be synthesized to protect the phenolic 
        Parameter Value 
 
R
2 
Hill co-efficient 
0.9727 
0.69  
(95% C.I: 0.57-0.81) 
Km 149 µM (Hill model) 
 (95% C.I: 86-213) 
Vmax 313 pmol/hr 
 (95% C.I: 280-345) 
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hydroxyl group, but the stability and toxicity of these prodrugs in the gastric fluid is 
unknown. This would require extensive investigation. Certain phenolic GRAS compounds 
which have structural features similar to PE can be substrate for this SULT enzymes and 
inhibit the metabolism of PE through sulfation pathway. The phenolic GRAS or dietary 
inhibitors that were selected for the study were propyl paraben, pterostilbene, quercetin, 
isoeugenol, eugenol, ethyl vanillin, raspberry ketone, magnolol, resveratrol, zingerone, 
vanillin and curcumin. 
3.3.3.1 Experimental Setup 
Start solutions containing 50 µM PE as the substrate and various GRAS compounds used as 
inhibitors having concentrations of 50, 10, 2, 0.4 µM were prepared. Stock solutions (25mM) 
of various GRAS compounds in DMSO was used and final DMSO concentrations were 
maintained at 0.5% v/v. 
In order to study the effect of these compounds on metabolism of PE, LS180 cells were 
treated with 250 µL of these start solutions with various inhibitor concentrations for 8 hours 
(from incubation time optimization study) at 37°C with 5% CO2. LS180 cells containing 
control samples with PE alone and no inhibitor were also incubated. At the end of 8 hours, 
the metabolic reactions were stopped using 1.0 mL ACN containing 24 μM E2-3G as the 
internal standard and analyzed as previously described. The samples at each concentration 
were prepared in triplicate.  
3.3.3.2 Results 
Data of inhibition of PES formation (8 hrs incubation, PE=50µM) in LS180 cells, were fitted 
to the equation Y=YMAX/[1+10
(X-IC50)
 ] fitted to the data obtained in the presence of various 
inhibitors.  YMAX was set to the average of 6 determinations in the absence of inhibitor 
(444±9 pmol/hr).  The model assumed: 1. no PES formation at maximal concentrations of the 
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inhibitor and 2. at 0 µM concentration of the inhibitor, the PES formation was 100% (bottom 
= 0 and top = 100 respectively). Also it was initially assumed to be a competitive inhibition 
and Hill co-efficient was not included in the model. Nonlinear regression output (GraphPad 
Prism v5) is shown in Figures 3.7, 3.8, 3.9, 3.10 and Table 5 (below).  
Figure 3.7 Inhibition of PES formation using eugenol, ethyl vanillin, magnolol and 
raspberry ketone  
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Ymax (control) of three determinations for Eugenol: 795 pmol/hr, Ethyl Vanillin: 795 pmol/hr, Magnolol: 550 
pmol/hr, Raspberry Ketone: 795 pmol/hr 
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Figure 3.8 Inhibition of PES formation using propyl paraben, pterostilbene, quercetin 
and isoeugenol 
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Ymax (control) of three determinations for Propyl Paraben: 720 pmol/hr, Pterostilbene: 484 pmol/hr, Quercetin: 
484 pmol/hr, Isoeugenol: 486 pmol/hr 
Figure 3.9 Inhibition of PES formation using resveratrol and zingerone 
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        Ymax (control) of three determinations for Resveratrol and Zingerone: 444 pmol/hr  
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Figure 3.10 Inhibition of PES formation using vanillin and curcumin 
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Ymax (control) of three determinations for vanillin: 506 pmol/hr and curcumin: 578 pmol/hr. 
 
Table 3.3 IC50 values for the inhibitors 
 
 
 
 
 
 
 
From the IC50 values obtained it was observed that resveratrol and eugenol were good 
inhibitors of PES formation using LS180 cell model as compared to other GRAS compounds.  
Compound IC50 (µM) 
 
95% C.I 
eugenol 3.5 3.0-4.0 
resveratrol 6.0 4.2-8.5 
zingerone 8.6 6.7-11 
isoeugenol 10 7.7-13 
ethyl vanillin 19 12-30 
quercetin 33 21-53 
pterostilbene 37 28-51 
propyl paraben 46 31-68 
raspberry ketone >50 - 
vanillin >50 - 
magnolol >50 - 
curcumin >50 - 
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In the previous studies curcumin showed a greater effect on preventing total PE 
disappearance. But curcumin showed low inhibition of sulfation of PE. Hence this tells us 
that curcumin may prevent the formation oxidation of PE and to a very less extent the 
formation of the sulfate metabolite. The calculated IC50 values obtained for raspberry ketone, 
vanillin, magnolol and curcumin were beyond the experimental range of the inhibitor 
concentration used. Hence the IC50 values are reported as greater than 50 µM. 
3.3.4 Investigation of the unknown metabolite 
From the PES saturation study, an unknown peak at about 1.9 minutes was observed with the 
HILIC assay method. The intensity of this unknown peak was found to increase 
proportionally with respect to the concentration of the substrate used. Also from the time 
course study with LS180 cell model, we know that there other pathways involved other than 
sulfation. Furthermore the unknown metabolite is less retained as compared to the sulfate 
metabolite on the HILIC column which is in line with our hypothesis that it could be an 
MAO metabolite as they are less hydrophilic as compared to the sulfate metabolite. 
The major metabolites of PE when given orally are sulfate and the MAO metabolite. Hence 
further experiments were done in order to confirm whether the unknown peak is an MAO 
metabolite. In an attempt to determine the structure of this metabolite, the HPLC eluent 
containing the unknown peak was collected and pooled from several injections of LS180 cell 
samples incubated with PE.  The eluent was concentration by evaporation, and injected using 
the HILIC method described above, but passing the column eluent through a Waters QDa 
mass detector (Waters Corp., Milford, MA) instead of the fluorescence detector.  Broad-range 
scanning from 150 to 300 Da in both positive ion and negative ion modes was performed.  
However, at the retention time of the unknown peak (1.9 minutes), no discernible peak 
masses were detected.  Additionally, small peaks at other retention times were seen but did 
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not  match with any expected molecular masses other than PE. Hence the identification of the 
unknown metabolite was not completed.  
3.3.4.1 Experimental setup 
The HILIC assay method developed was used in order to study the PES formation. LS180 
cells were seeded at a concentration of 1.9 x 10
5
 cells/mL in the 24 well plate (14). The 
experiment was carried out on the 4
th
 day after plating the cells (14). Hence the effect of the 
following MAO inhibitors on the intensity of the unknown peak was investigated: 
Table 3.4 Type and concentration of MAO inhibitors used (22) 
 
The concentrations of MAO inhibitors used were much above the IC50 value for that 
particular MAO-A or MAO-B activity in order to ensure nearly complete inhibition of the 
formation of the MAO metabolite. The concentrations were chosen in such a way that it is 
much above the IC50 value for the particular enzyme it is selective for and much below the 
IC50 value for the particular MAO enzyme it is non-selective. The concentrations of selegiline 
and clorgyline used were based on IC50 values obtained from the literature. The concentration 
of clorgyline used was 10 times more than the IC50 value for MAO-A but it was much less as 
compared to IC50 value for MAO-B. Similarly the concentration of selegiline used was 10 
times higher than IC50 value of MAO-B and much less than IC50 value for MAO-A. The 
concentrations for resveratrol and pterostilbene were selected based on IC50 values obtained 
from previous work done in the lab (14). The concentration of resveratrol used was 10 times 
Inhibitor Target 
 
IC50 values( µM) 
   MAO-A                 MAO-B 
Concentration 
(µM) 
pargyline Non-selective - - 10.00 
selegiline MAO-B 1.7 0.01 0.08 
clorgyline MAO-A 0.016 3.5 0.16 
resveratrol MAO-A 0.3 15.8 3.00 
pterostilbene MAO-B 13.4 0.14 1.40 
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more than the IC50 value for MAO-A but it was much less as compared to IC50 value for 
MAO-B. Similarly the concentration of pterostilbene used was 10 times higher than IC50 
value of MAO-B and much less than IC50 value for MAO-A. This was done so that they 
selectively inhibit either MAO-A or MAO-B. In order to study the effect of these MAO 
inhibitors on the formation of the unknown metabolite, LS180 cells were treated with 250 µL 
of these start solutions with various inhibitor for 5 hours (from incubation time optimization 
study) at 37°C with 5% CO2. The concentration of PE used was 50 µM. LS180 cells 
containing control samples with PE alone and no inhibitor were also incubated. At the end of 
5 hours, the metabolic reactions were stopped using 1.0 mL ACN containing 24 μM E2-3G 
as the internal standard. The samples were processed in the same way as described earlier. 
The samples at each concentration were prepared in triplicate.  
Figure 3.11 Inhibition of the unknown metabolite in presence of MAO inhibitors 
U n k n o w n  P e a k  (1 .9  m in s )
C
o
n
tr
o
l 
p
a
rg
y
li
n
e
 1
0
M
s
e
le
g
il
in
e
 0
.0
8

M
c
lo
rg
y
li
n
e
 0
.1
6
M
re
s
v
e
ra
tr
o
l 
3

M
p
te
ro
s
t i
lb
e
n
e
 1
.4

M
0
1
2
3
P
A
R
 o
f 
u
n
k
n
o
w
n
 p
e
a
k
/E
2
-3
G
* *
*
*
*
 
 
 40 
Figure 3.12 Inhibition of the PES formation in presence of MAO inhibitors 
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Figure 3.13 Amount of PE remaining in presence of MAO inhibitors 
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3.3.4.2 Results 
From the data obtained from the figure 3.11 it was observed that pargyline (non-selective for 
MAO-A and MAO-B at a high concentration of 10 µM) and clorgyline (selective inhibitor 
for MAO-A at low concentration) almost completely inhibit the formation of the unknown 
metabolite whereas the formation of the unknown metabolite is statistically significantly 
inhibited in presence of selegiline which is a selective inhibitor for MAO-B. Hence we can 
infer that the unknown compound is mainly an MAO-A metabolite. Also the amount of PE 
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remaining with pargyline and clorgyline was not greater than 15% with respect to the control. 
This tells us that MAO pathway is a minor pathway for metabolism of PE in the LS180 cell 
model at 50 µM PE. Structural elucidation of this metabolite was not achieved. The possible 
reason could be, 3-hydroxy mandelaldehyde which is one of the metabolite of MAO pathway 
is highly reactive and can form combination products in presence of cellular amines. 
Carbonyl compounds like 3-hydroxy mandelaldehyde react with amines to form Schiff bases 
which are combination products from various possibilities, hence it becomes difficult to 
determine their structures. Also 3-hydroxy mandelaldehyde can react with aldehyde 
dehydrogenase to form an oxidation product that is 3-hydroxy mandelic acid. Also the 
contribution of the sulfation and MAO pathway could not be determined due to lack of 
identification of the unknown MAO metabolite(s).  
3.4 Discussion 
LS180 cell model served as a good source to investigate the sulfation of PE. The optimization 
experiments with the cell model helped in determining the incubation time and the substrate 
concentration to be used in order to test the effect of GRAS compounds on inhibition of 
formation of PES. From the IC50 values obtained with GRAS compounds using the LS180 
cell model, resveratrol and eugenol showed highest inhibitory activity and were chosen for 
further studies with recombinant SULTs and HIC. The metabolism of PE in LS180 cells 
could be inhibited either at the entry step in to the cell, or after getting in to the cell, it inhibits 
the SULT enzyme. Further studies with recombinant SULTs and HIC were done in order to 
confirm the same. At this point it was of interest to determine which SULT enzyme is 
majorly responsible for sulfation of PE and also to determine the mechanism of inhibition 
with GRAS compounds using HIC. The study with MAO inhibitors (selective for MAO-A 
and MAO-B) suggested that the unknown metabolite is mainly an MAO-A metabolite. 
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4 Determination of PES formation in in vitro systems like 
Recombinant Enzymes and Human Intestinal Cytosol  
4.1 Introduction 
Experiments done using LS180 human intestinal cell model demonstrated inhibition of PE 
sulfation. Recombinant enzymes are over expressed systems and have greater total activity 
(per mg of total protein) than those produced by native sources. The advantages of using this 
recombinant enzyme system are the lack of interfering enzymes activity present in the cytosol 
and microsomes of cells, the flexibility to optimize reaction components, and the high 
expression level of the enzyme (thus facilitating product detection). It also helps in 
identifying the isoform responsible for metabolism, kinetic analysis, inhibitor screening and 
metabolite production. For isoform identification, recombinant enzymes are used to correlate 
the data obtained from microsomes or cytosol. Previous studies have demonstrated that 
SULT1A3 is expressed in many organs including the brain, gastrointestinal tract, kidney, 
liver and lung (23, 24). In order to further investigate the metabolism of PE, studies were 
done using recombinant SULT1A3 and human intestinal cytosol (HIC). The work done by 
Yamamoto et.al. suggested that SULT1A3 was the major human SULT responsible for the 
sulfation of phenylephrine (9). Taskinen et al. determined the sulfation rates for 53 catechol 
 
 44 
compounds by six expressed human SULT isoforms and found the highest activity and 
broadest reactivity with SULT1A3 (25). 
The studies also revealed that the kinetics of SULT1A3-mediated sulfation of phenylephrine 
appeared to be in the same order of magnitude as that of sulfation of dopamine (9). The Km 
value of phenylephrine was 17.54 µM, and the Vmax /Km (mL/min/mg) was 1.92 (9). The 
reported Km values of SULT1A3 toward dopamine ranged 2.2 to 8.56 µM and the Vmax/Km 
(mL/min/mg) ranged 9.73 to 228 (9). This can be due to the structural similarity between 
dopamine and phenylephrine. Mutagenesis studies and analysis of the crystal structure of 
SULT1A3 indicate that Glu146 is primarily responsible for the differences in the substrate 
specificity of SULT1A3 compared to SULT1A1 (26). The presence of the Glu146 is also 
proposed to interact with the Tyr240 residue to enhance hydrogen bonding with catechols 
(26). Overall rates of sulfation with SULT1A3 in the intestine tend to be higher than the liver 
(up to 10-fold) (10, 12). 
Thus intestine represents a considerable barrier to the oral bioavailability of sulfotransferase 
substrate drugs (10, 12, 27). Human intestinal cytosol would provide an enzyme source with 
a physiologic expression level of SULTs. 
4.2 Objective 
The objective of the presented work to check the feasibility of the GRAS or dietary 
compounds on inhibition of PES formation using recombinant enzymes and HIC which 
would help in depicting a picture closer to the physiological level. The specific aims included 
(1) Optimization experiments using SULT1A3 and HIC (2) Generation an IC50 curve for 
resveratrol using HIC. (3) Determination of the mechanism of inhibition of PES formation 
using resveratrol in HIC system. 
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4.3 Methods 
Human SULT1A3, 1 µg/mL protein (Cypex) batch no: S1A3002A and Catalogue no: 
CYP101 was used. PAPS (Sigma) was used and stock was prepared in pH 8.0 phosphate 
buffer. The concentration of PAPS in the body is approximately 23 nmoles/g body tissue.(28) 
Assuming a tissue density of ~1g/ml, it approximates 23 µM.  The intestinal concentration of 
PAPS is a bit lower (14 nmoles/g), hence 20 µM is used typically.(28) All the solutions were 
prepared in water and pH of potassium phosphate solution was adjusted to 7.4 with potassium 
hydroxide solution. The following experimental design was setup based on the supplier’s 
specifications.  
4.3.1 Incomplete reaction solution 
Table 4.1 Incomplete reaction solution 
 
Component 
Stock 
Concentration 
Potency (X) Desired final 
conc. 
Stock Volume to 
add (µL) 
Potassium 
Phosphate, pH 7.4 
100 mM
 
2 50mM 375 
Dithiothreitol 
(DTT) 
1M 100 10mM 7.5 
Magnesium 
Chloride 
Enzyme 
(SULT1A3) 
Substrate: PE 
BSA 
1M 
 
10µg/uL 
 
5mM 
1%w/v 
200 
 
1000 
 
500 
20 
5mM 
 
1µg/mL 
 
10µM 
0.05%w/v 
3.75 
 
0.75 
 
1.5 
42.5 
Water (q.s to 
volume) 
  - 244 
Trigger solution: added to incomplete reaction solution 
PAPS            200 µM 10 20µM 75 µL 
 
The enzyme was thawed on ice and incomplete reaction mixtures were prepared as listed in 
table 4.1 and kept on ice. Trigger solution (PAPS 5µL) was aliquoted in PCR tubes. To this 
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trigger solution 45 µL of incomplete reaction was added and mixed well. Care should be 
taken not to add the trigger solution to the bulk incomplete reaction solution, or the 
experimental design is ruined. The reaction times were 10 minutes and 60 minutes at 37°C. In 
order to stop the PES reaction, ACN (4 volumes) was added. The samples (n=3) were then 
centrifuged at 6000g for 13 minutes at 4°C. Supernatant (25 µL) was injected into the HPLC 
system. Blank samples were also prepared using only water instead of the trigger solution 
(PAPS) to check for any interferences. E2-3G was not used for SULT1A3 assay as there was 
no involvement of the extraction procedure as done for the cell-based assays. There was no 
blank interference observed. This study provided a good estimate for the incubation time (less 
than 60 minutes) to be used and also confirmed that PES formation could be detected using 
the same HILIC assay used for the cell-based assays. 
 
4.3.2 Preparation of standard curves 
Standard curve stock solution (A) 
ACN (12 mL), 1.5 mL of potassium phosphate (100 mM pH 7.4), 30 µL of DTT (1M), 15 µL 
of MgCl2 (1M) and 1.48 mL water were mixed. Note: potassium phosphate (100mM) is 
expected to form precipitate in 80% ACN.  
Preparation of first standard containing 200 µM PE and 32 µM PES 
Stock solution A (399.5 µL), 0.52 µL of PES (31mM PES), 100 µL of PE (1 mM) were 
added and mixed. 
Serial dilutions were done using this first standard. To 250 µL of higher concentration of 
standard, 250 µL of stock solution A was added.  Standard solutions containing PE (200, 100, 
 
 47 
50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39 µM) and PES (32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 
0.0625 µM) were prepared. 
 
4.3.3 Chromatographic conditions 
Preparation of buffer for mobile phase: To 250 mL of HPLC grade water, 1250 µL of TEA 
and 780 µL of ammonium hydroxide was added. pH was adjusted to 4.5 with formic acid. 
Mobile phase A:  ACN: MeOH: Buffer (72: 8: 20) 
Mobile phase B: 100% ACN 
Separation of analytes was performed using a Phenomenex EC 100X4.6 mm Nucleodur 
HILIC, 3µm (Macherey – Nagel) column preceded by a HILIC Security Guard Cartridge. 
The HPLC system (Waters) consisted of the Alliance 2695 separations module and a 2475 
fluorescence detector. Data were collected and analyzed using Empower 2 or Empower 3 
software. 
Determination of PE, PES and E2-3G was performed withµ isocratic elution (mobile phase 
A: mobile phase B, 90:10) at a flow rate of 0.8 mL/min. The injection volume was 25 µL. 
The runtime was 6.0 mins. The column temperature was maintained at 30°C and the 
autosampler compartment was set to 4°C. PE and PES were detected at the excitation 
wavelength of 268 nm and emission wavelength of 293 nm with retention times as follows: 
PES: 3.2 minutes, PE: 4.3 minutes. 
4.3.4 Time course study with SULT1A3 
4.3.4.1 Experimental setup 
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In order to optimize the incubation time with SULT1A3 the same experimental setup was 
used as discussed in Table 4.1. Standard curves were prepared in the same way as described 
in section 4.3.2. The incubation was terminated at 0, 15 and 30 minutes with 5 µM and 200 
µM PE 
 
Figure 4.1 Time course of PES formation with SULT1A3 at 5 µM PE 
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Figure 4.2  Time course of PES formation with SULT1A3 at 200 µM PE 
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                              R
2 
= 0.9730, Slope = 28 pmoles/min (95% C.I: 26 - 31) 
4.3.4.2 Results  
The formation rate of PES was linear up to 30 minutes with 5 µM and 200 µM PE with good 
R
2
 estimates. When slopes of this linear regression were compared at 5 µM and 200 µM PE, 
it was also observed that formation rate of PES was saturated with increasing substrate 
concentration from 5 µM to 200 µM. Clearance (CL) is the ratio of metabolism or excretion 
rate (dx/dt) and concentration (C). So although the actual formation rate is higher at the 
higher concentration, when formation rate is normalized to concentration, a decrease in 
clearance is observed as the system approaches saturation. This tells us that the enzyme is 
saturated at higher substrate concentrations and hence the sulfation pathway is a saturable 
process. At higher substrate concentrations the contribution of sulfation pathway is reduced 
as compared to lower substrate concentrations. From this study the chosen incubation time 
was 15 minutes in order to study the enzyme kinetic parameters using SULT1A3. 
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4.3.5 Optimization of concentration of BSA to be used 
Bovine serum albumin is added to prevent non-specific binding of the protein and also it 
stabilizes the protein in the solution. During the time course study, non-specific binding of 
protein and/or inactivation were observed at lower concentration of SULT1A3 (0.25µg/mL). 
For this study 1% w/v of BSA solution was prepared using pH 7.4 phosphate buffer solution. 
Substrate concentration of PE used was 5µM and formation rate of PES was determined 
using 0%, 0.01%, 0.025% and 0.05% w/v BSA solutions. Reaction mixture was prepared as 
mentioned in Table 4.1. In order to stop the PES formation, ACN (4 volumes) was added. 
The samples (n=3) were then centrifuged at 6000g for 13 minutes at 4°C. Supernatant (25 
µL) was injected into the HPLC system. The same HILIC assay method was used in order to 
analyze the samples. Standard curve was prepared as described under 4.2.2. 
                  
Figure 4.3 PES formation using various concentrations of BSA 
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It was observed at 0.05% w/v BSA, the effect of BSA appeared optimal (a five-fold increase 
in PES formation) and hence 0.05% w/v BSA was selected as the BSA concentration to be 
used for further optimization experiments. 
4.3.6 Optimization of protein concentration to be used for SULT1A3 assay 
4.3.6.1  Experimental setup 
In order to optimize the protein (SULT1A3) concentration to be used for SULT1A3 assay the 
same experimental setup was used as discussed in Table 4.1. The study was done at 0.25 
µg/mL, 0.5 µg/mL, 1.0 µg/mL and 2.0 µg/mL protein. Substrate concentrations used were 5 
µM and 200 µM PE. BSA (0.05%w/v) was also added to the reaction mixture. Sample 
preparation was done in triplicate. Standard solutions was prepared as described under 4.2.2.   
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Figure 4.4  PES formation using various concentrations of SULT1A3 at 5 µM PE     
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Figure 4.5 PES formation using various concentrations of SULT1A3 at 200 µM PE 
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            Slope = 8.6  pmoles/min/µg/mL protein (95% C.I: 8.4-8.9) 
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4.3.6.2 Discussion  
The SULT1A3 enzyme protein concentration was optimized to 1.0 µg/mL as it was found in 
the linear range and had good R
2
 estimates at both 5 µM and 200 µM PE as shown in Figures 
4.4 and 4.5. 
4.3.7 Saturation of PES formation with SULT1A3 
4.3.7.1 Experimental Setup 
In order to optimize the substrate concentration to be used for further studies for SULT1A3 
assay, the same experimental setup was used as discussed in Table 4.1. The study was done at 
200, 100, 50, 25, 12.5, 6.25, 3.12 µM PE. The SULT1A3 protein concentration used was 1.0 
µg/mL and the reaction time was 15 minutes with 0.05% w/v BSA as previously optimized. 
At the end of 15 minutes the metabolic reactions were stopped with 200 µL ACN. The 
samples (n=3) at each substrate concentration were then centrifuged at 6000g for 13 minutes 
at 4°C. Supernatant (25 µL) was injected into the HPLC system. The same HILIC assay was 
used as described under 4.2.3. The Michaelis-Menten non-linear regression model was used 
to fit the data using Graph Pad Prism v5 software.
 
 54 
 
Figure 4.6 Saturation of PES formation with SULT1A3 
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Protein Concentration used = 1 µg/mL 
                                                          
 
Table 4.2 Enzyme kinetic parameters using SULT1A3 enzyme 
 
 
 
 
  
        Parameter Value 
 
Km 65 µM  
(95% CI: 58.1 to 71.2) 
Vmax 211 pmol/min/µg protein 
(95% CI: 202 to 220) 
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4.3.7.2 Results 
It was observed that the formation of PES is a saturable process at higher concentrations of 
PE (Figure 4.6). The Km value observed for PE with SULT1A3 enzyme was 65 µM (Table 
4.2) which was almost two fold lower as compared to those observed with the LS180 cell 
model which was 149 µM. This difference in Km can be attributed to the permeability of PE 
into the LS180 cells. Vmax obtained with SULT1A3 and LS180 cell model could not be 
compared as the Vmax for LS180 cell model was not normalized with amount of SULT1A3 
protein present in the cells. This study gave a fair idea of the substrate concentration to be 
used for inhibitor screening below Km value that is 65 µM.  
4.3.8 Screening of inhibitors (GRAS compounds/dietary compounds) with SULT1A3 
In order to study the mechanism of inhibition, various GRAS compounds were tested to 
select the best GRAS compound with maximum inhibitory activity on PES formation. The 
GRAS/dietary compounds that were tested are resveratrol, eugenol, isoeugenol, pterostilbene, 
raspberry ketone, magnolol, propyl paraben, methyl paraben, zingerone, ethyl vanillin. 
Almost complete inhibition of PES formation was seen at 50 µM with these GRAS 
compounds with LS180 cell model, hence 30 µM of inhibitor concentration was selected to 
test the inhibitory activity of these GRAS compounds using SULT1A3. At 30 µM inhibitor 
concentration the PES formation would be above LLOQ of the method and hence it would be 
quantifiable. The substrate concentration of 15 µM was chosen which was well below Km 
value based on the PES formation saturation study with SULT1A3. Hence the formation of 
PES would be linear with respect to substrate concentration used.  
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Figure 4.7  Inhibitor Screening with SULT1A3 
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< LLOQ
PE = 15 µM and Inhibitor = 30 µM. The error bar represents (±S.D). 
4.3.8.1  Results 
One way ANOVA analysis with a Dunnett’s post-hoc test was used to compare the PES 
formation using various inhibitors with respect to control. Significant inhibition was seen was 
seen with almost all of the inhibitors except methyl paraben and pterostilbene. The highest 
inhibition of PES formation was seen with resveratrol. Hence resveratrol was selected to 
study the mechanism of inhibition study.   
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4.3.9 Time course study with Human intestinal cytosol (HIC) 
Human intestinal cytosol (HIC) (mixed gender, 4mg/mL) was obtained from Xenotech, LLC 
(Lexena, KS) was prepared from mature enterocytes of the subcellular fractionization of 
intestinal villus tips. 
4.3.9.1 Experimental setup 
Table 4.3 Incomplete reaction solution 
 
Component 
Stock 
Concentration 
Potency (X) Desired final 
conc. 
Stock Volume 
to add (µL) 
Potassium 
Phosphate, pH 7.4 
100 mM
 
2 50mM 375 
Dithiothreitol 
(DTT) 
1M 100 10mM 7.5 
Magnesium 
Chloride 
HIC 
Substrate: PE 
BSA 
1M 
 
4 mg/mL 
5mM 
1%w/v 
200 
 
16 
500 
20 
5mM 
 
250 µg/mL 
10µM 
0.5%w/v 
3.75 
 
42.20 
           1.5 
         33.75 
Water (q.s to 
volume) 
  - 170.1 
Trigger solution: added to incomplete reaction solution 
PAPS            200 µM 10 20µM 75 µL 
 
The enzyme source (HIC) was thawed on ice and incomplete reaction mixtures were prepared 
as above and kept on ice. Trigger solution (PAPS 200µM,  5µL) was aliquoted in PCR tubes. 
To this trigger solution 45 µL of incomplete reaction was added and mixed well. Care should 
be taken not to add the trigger solution to the bulk incomplete reaction solution, or the 
experimental design is ruined. The time points used for the study were 0, 10, 20 and 30 
minutes at 37°C at 5 µM and 200 µM PE. In order to stop the PES reaction, ACN (4 
volumes) was added. The samples (n=3) were then, centrifuged at 6000g for 13 minutes at 
4°C. Supernatant (25 µL) was injected into the HPLC system.  And blank samples were also 
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prepared using only water instead of the trigger solution (PAPS) to check for any 
interferences. E2-3G was not used for HIC assay as there was no involvement of the 
extraction procedure as done for the cell-based assays. There was no blank interference 
observed. This study provided a good estimate for the incubation time to be used and also 
confirmed that PES formation could be detected using the same HILIC assay used for the 
cell-based assays. 
Figure 4.8 Time course study with HIC at 5 µM PE 
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Slope = 11.8 ± 0.3 pmoles/min (95% C.I: 11.2 – 12.3), R
2 
= 0.9952 
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Figure 4.9 Time course study with HIC at 200 µM PE 
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Slope = 127 ± 1 pmoles/min (95% C.I: 124 – 129), R
2 
= 0.9992 
4.3.9.2 Results 
The formation rate of PES was linear up to 30 minutes with 5 µM and 200 µM PE with good 
R
2
 estimates. When slopes of this linear regression were compared at 5 µM and 200 µM PE, 
it was also observed that formation rate of PES was saturated with increasing substrate 
concentration from 5 µM to 200 µM. This tells us that the enzyme may be saturated at higher 
substrate concentrations, consistent with the sulfation pathway being a saturable process. At 
higher substrate concentrations the contribution of sulfation pathway is reduced as compared 
to lower substrate concentrations. From this study the incubation time was optimized to 30 
minutes in order to study the enzyme kinetic parameters using HIC.  
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4.3.10 Optimization of protein concentration to be used for HIC assay 
4.3.10.1  Experimental Setup 
In order to optimize the HIC protein concentration to be used for HIC assay the same 
experimental setup was used as discussed in section 4.8.1. The study was done at 0 µg/mL, 
250 µg/mL and 500 HIC µg/mL protein. Substrate concentrations used was 5 µM and 200 
µM PE. BSA (0.05%w/v) was also added to the reaction mixture. Sample preparation was 
done in triplicate. Standard solutions was prepared as described under 4.2.2.  
Figure 4.10 PES formation using various concentrations of HIC at 5 µM PE 
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R
2 
= 0.9993; slope = 1.94 (pmol/min)/µg HIC protein 
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Figure 4.11 PES formation using various concentrations of HIC at 200 µM PE 
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R
2 
= 0.9962. Slope = 24 (pmol/min)/µg HIC protein 
4.3.10.2  Discussion  
The protein concentration of HIC chosen for further studies was 250 µg/mL as it was in the 
linear range of PES formation rate. The slopes of the graphs at 5 µM and 200 µM PE, when 
normalized for PE concentrations, demonstrate evidence of a saturable process. 
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4.3.11  Saturation of PES formation with HIC 
4.3.11.1 Experimental Setup 
In order to optimize the substrate concentration to be used for further studies for HIC assay, 
the same experimental setup was used as discussed in section 4.8.1. The study was done at 
200, 100, 50, 25, 12.5, 6.25, and 3.12 µM PE. The protein concentration used was 250 µg/mL 
and the reaction time was 30 minutes. At the end of 30 minutes the metabolic reactions were 
stopped with 4 volumes of ACN. The samples (n=3) at each substrate concentration were 
then centrifuged at 6000g for 13 minutes at 4°C. Supernatant (25 µL) was injected into the 
HPLC system. The same HILIC assay was used as described under 4.2.3. The Michaelis-
Menten non-linear regression model was fitted the data obtained using Graph Pad Prism v5 
software. 
 
 
 
 63 
Figure 4.12 Saturation of PES formation with HIC 
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Table 4.4 Enzyme kinetic parameters using HIC 
 
 
 
  
        Parameter Value 
 
Km 73 µM  
(95% CI: 66.0 to 79.1) 
Vmax 0.88 pmol/min/µg protein 
(95% CI: 0.85 to 0.92) 
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4.3.11.2 Results 
The Michaelis Menten model was fitted to the data (from Figure 4.12 and Table 4.4) and non-
linear regression analysis was performed. It was observed that the formation of PES is a 
saturable process at higher concentrations of PE. The Km value observed for PE with HIC was 
73 µM (95% CI: 66.0 to 79.1) and with SULT1A3 was 65 µM (95% CI: 58.1 to 71.2). Thus 
there is no statistically significant difference in Km values. The Vmax value obtained with HIC 
is almost 240 fold lower per mg of total protein as compared to the Vmax value obtained with 
SULT1A3. This is due to the enriched expression level of the recombinant SULT1A3 as 
compared to HIC which has presence of many other proteins too. This study gave a guidance 
for the choice of non-saturating substrate concentrations to be used for further experiments. 
4.3.12  IC50 Curve for Resveratrol using HIC 
4.3.12.1 Experimental Setup 
Based on the inhibitor screening data obtained from the SULT1A3 experiments, resveratrol 
was selected as the inhibitor with the maximum inhibitory capacity among the tested GRAS 
compounds. In order to estimate the IC50 value for resveratrol using HIC- 0, 3.5, 7 and 21 µM 
of inhibitor concentrations of resveratrol were used. The substrate concentration of PE used 
was 50 µM and concentration of HIC used was 250 µg/mL. Control samples were also 
prepared with no inhibitor (0 µM). The same experimental setup was used as described under 
section 4.8.1 and Table 4.3. The reaction time was 30 minutes and the end of 30 minutes the 
metabolic reactions were stopped with 200 µL (4 volumes) of ACN. The samples (n=3) at 
each substrate concentration were then centrifuged at 6000g for 13 minutes at 4°C. 
Supernatant (25 µL) was injected into the HPLC system. The same HILIC assay was used as 
described under 4.2.3.  
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Figure 4.13 IC50 curve for Resveratrol 
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Control rate was 0.391 pmoles/min/µg protein 
 
4.3.12.2 Results 
The equation Y=YMAX/1+10
(X-IC50) 
was used to fit the data (figure 4.13) of inhibition of PES 
formation (30 minutes incubation, PE=50µM using HIC, were fitted to in the presence of 
various inhibitors concentrations of resveratrol.  YMAX was set to the average PES 
formation rate from 3 determinations in the absence of inhibitor (0.391 pmoles/min/µg 
protein). The model assumed that there was no PES formation at infinitely high 
concentrations of the inhibitor and at 0 µM concentration of the inhibitor, the PES formation 
was 100% (i.e. bottom = 0 and top = 100). Hill co-efficient was not included in the model. 
The IC50 non-linear regression model was fitted to the data (Figure 4.13) using GraphPad 
Prism v5 software. The IC50 value obtained was 12 µM (95% C.I: 9.7-14). This IC50 value 
gave a fair idea of the concentration range of the inhibitor to be used for the mechanism of 
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inhibition study using HIC. Assuming competitive inhibition, the Ki value (~7 µM) was 
calculated using this IC50 value using Cheng and Prusoff equation using GraphPad Prism 5. 
This Ki value was used to determine the inhibitor concentrations (0.5x, 1x, 3x Ki) to be used 
for the mechanism of inhibition experiment. 
4.3.13  Determination of mechanism of inhibition 
4.3.13.1 Experimental Setup  
In order to determine the mechanism of inhibition of PES formation using resveratrol in the 
HIC system, the same experimental setup was used as discussed in Section 4.8.1. The study 
was done at 200, 100, 50, 25, 12.5, 6.25, 3.12 µM PE and 0, 3.5, 7 and 21 µM PE. The 
protein concentration used was 250 µg/mL and the reaction time was 30 minutes. At the end 
of 30 minutes the metabolic reactions were stopped with 200 µL ACN (4 volumes). The 
samples (n=3) at each substrate concentration were then centrifuged at 6000g for 13 minutes 
at 4°C. Supernatant (25 µL) was injected into the HPLC system. The same HILIC assay was 
used as described under 4.2.3. The non-linear regression model was used to fit the data using 
GraphPad Prism v5 software.  
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4.3.13.2  Results 
  
Figure 4.14 Fit of non-competitive inhibition model on a linear scale  
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Figure 4.15 Fit of non-competitive inhibition model on a semilog scale 
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Equation used for non-competitive inhibition model 
V= [Vmax/(1+I/Ki)]* [S]/[Km+S] 
 
In this case Vmax is decreased by a factor of (1+I/Ki) 
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Figure 4.16 Fit of competitive inhibition model on a linear scale 
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Figure 4.17 Fit of competitive inhibition on a semi-log scale                                 
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Equation used for competitive inhibition model 
V= Vmax[S]/[Km(1+I/Ki)+S] 
In this case Km(app) is increased by a factor of (1+I/Ki) 
Ki = dissociation constant of an inhibitor when it binds to the enzyme only 
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Figure 4.18 Fit of uncompetitive inhibition model on a linear scale  
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Figure 4.19 Fit of uncompetitive inhibition on a semi-log scale                               
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Equation used for uncompetitive inhibition model 
V= {[Vmax/(1+I/Ki
’
)]*[S]}/{[Km/(1+I/Ki
’
)+S]} 
In this case both Km(app) and Vmax(app) are increased by a factor of (1+I/Ki
’
) 
Ki
’
 = dissociation constant of an inhibitor when it binds to the enzyme-substrate complex  
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Figure 4.20 Fit of mixed inhibition model on a linear scale  
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Figure 4.21 Fit of mixed inhibition model on a semi-log scale                                                 
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Equation used for mixed inhibition model 
V= {[Vmax/(1+I/Ki
’
)]*[S]}/{[Km(1+I/Ki)/(1+I/Ki
’
)+S]} 
In this case both Km(app) can either be increased or decreased and Vmax(app) is decreased 
by a factor of (1+I/Ki
’
) 
Ki
’
 = dissociation constant of an inhibitor when it binds to the enzyme substrate complex 
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Table 4.5 Comparison for models of inhibition 
 
 
        Parameter Competitive inhibition
 
 
Non-competitive 
inhibition 
Uncompetitive      
inhibition 
Mixed inhibition 
R
2
 0.9667 0.9716 0.9431 0.9738 
Km (µM) 69 
(95% CI: 49.7 to 87.6) 
96 
(95% CI: 75.0 to 117) 
141  
(95% CI: 89.2 to 193) 
81  
(95% CI: 59.1 to 104) 
Vmax (pmol/min/µg 
protein) 
0.71 
(95% CI: 0.626 to 0.789) 
0.82 
(95% CI: 0.734 to 0.910) 
0.97  
(95% CI: 0.767 to 1.17) 
0.76  
(95% CI: 0.672 to 0.858) 
Ki (µM) 3.34 
(95% CI: 2.53 to 4.15) 
8.91 
(95% CI: 7.48 to 10.4) 
4.31 (αKi) 
(95% CI: 2.97 to 5.65) 
5.75 
(95% CI: 3.04 to 8.46) 
α - - - 2.51  
(95%C.I: 0.0-5.30) 
Model selection 
criteria  
(MSC) 
-1.9233 -1.8689 -1.9345 -3.9396 
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When mechanistic fit model of competitive vs non-competitive inhibition, non-competitive 
vs uncompetitive, mixed vs non-competitive inhibition were compared, the preferred model 
was non-competitive inhibition in all cases. There were three parameter estimates (Vmax, Km 
and Ki) for competitive, non-competitive and uncompetitive inhibition model whereas the 
mixed model inhibition included (Vmax, Km and Ki and a constant α). When goodness of fit 
was compared across the four models (competitive, non-competitive, uncompetitive and 
mixed inhibition), highest R
2
 values were obtained for the mixed inhibition and non-
competitive inhibition model. Also the values of the parameter estimates (Km and Vmax) 
obtained for the non-competitive model were closer to the values obtained from the PES 
formation saturation study with HIC with tight 95% confidence intervals. Model Selection 
Criteria was used to compare the models as the models had different number of parameter 
estimates.  MSC calculations were done as follows: 
R
2
 = 1-(SSQ/TSQ) 
                                   MSC = [ln(SSQ/TSQ)]-2p/n                             (30) 
Where SSQ = sum of squares, TSQ = total sum of squares, ln = natural log, p = number of 
parameter estimates, n = sample size 
The highest MSC value was obtained for the non-competitive inhibition and hence non-
competitive inhibition model was selected. The Ki values obtained from different models 
were comparable. It appears to be non-competitive inhibition since Km values are comparable 
across the concentration range of the inhibitor used whereas the Vmax decreases with the 
increase in inhibitor concentration because the enzyme is not catalytically efficient in 
presence of the inhibitor. During non-competitive inhibition, inhibitor either binds to the 
enzyme or the enzyme-substrate complex as shown in Figure 4.22. 
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The possible reason for this non-competitive inhibition could be due to the product inhibition 
caused due to PAP or depletion of PAPS. At higher concentrations of the inhibitor more 
amount of PAP is formed which inhibits the PES formation. Also it might bind to SULT1A3-
PE complex and prevent the conversion of PE to PES, although further studies needs to be 
done in order to confirm this hypothesis. The amount of PAP into the reaction mixture needs 
to be analyzed at the end of 30 minutes. The major drawback of this study was that the range 
of the substrate concentration used was not wide enough to have a better confidence on the 
parameter estimate values. It was observed from linear and log linear plots for all the four 
models that the PES formation was not completely saturated even at the highest substrate 
concentrations. 
 
Figure 4.22 Kinetic scheme illustrating noncompetitive binding (31)  
 
E = enzyme, S = Substrate, P = Product, ES = Enzyme-substrate complex, EI = Enzyme-
inhibitor complex, ESI = Enzyme-substrate-inhibitor complex  
  
 
 74 
 
Table 4.6 Table indicating enzyme kinetic parameters for non-competitive inhibition 
Conc. of inhibitor 
(µM) 
0 3.5 7 21 Global (shared) 
Noncompetitive 
inhibition 
     
Best-fit values 
     
Vmax 0.822 0.822 0.822 0.822 0.822 
I = 0.0 = 3.50 = 7.00 = 21.0 
 
Ki 8.91 8.91 8.91 8.91 8.91 
KM 95.9 95.9 95.9 95.9 95.9 
Std. Error 
     
Vmax 0.0438 0.0438 0.0438 0.0438 0.0438 
Ki       0.711      0.711       0.711      0.711         0.711 
KM        10.4       10.4        10.4       10.4          10.4 
95% Confidence 
Intervals 
     
Vmax 0.734-0.910 0.734-0.910  0.734-0.910 0.734-0.910 0.734-0.910 
 
 75 
Ki 7.48 to 10.4 7.48 to 10.4 7.48 to 10.4 7.48 to 10.4 7.48 to 10.4 
KM 75.0 to 117 75.0 to 117 75.0 to 117 75.0 to 117 75.0 to 117 
Goodness of Fit 
     
Degrees of Freedom 
    
45 
R square 0.9922 0.9489 0.9095 0.9617 0.9716 
Absolute Sum of 
Squares 
0.00291 0.0114 0.0130 0.00146 0.0288 
                                                                   
4.4 Discussion  
Kinetic studies done with the recombinant SULT1A3 and the data available in the literature 
(9) indicated that SULT1A3 is the major enzyme responsible for sulfation of PE. The Km 
values obtained with HIC and SULT1A3 were comparable whereas the Vmax values for 
SULT1A3 were more than 200-fold higher as compared to HIC. This can be attributed to 
higher expression of SULT1A3 in the recombinant system, although experiments with HIC 
would be physiologically more relevant. The optimization experiments done with SULT1A3 
and HIC indicated the reaction conditions to be used for the PES formation saturation studies. 
Although the mechanism of inhibition experiment indicated that there might be non-
competitive inhibition mechanism involved, further studies needs to be done in order to 
confirm the same. This non-competitive inhibition can be due to the product inhibition caused 
by PAP or might be resveratrol is binding to different binding site other than PE on the 
protein. 
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5 Overall Conclusions, Limitations and Future Directions 
 
The efficacy of PE is controversial due to its extensive pre-systemic metabolism through 
sulfation to form PES. Hence quantitation of PES is essential in order to study the 
metabolism of PE. There are no published methods available for direction detection of PES. 
Methods are available for the determination of PE in pharmaceutical formulations by HPLC 
method using ion-pair and hydrophilic interaction liquid chromatography (HILIC) coupled 
with fluorescence detection as described by Dousa et.al. (15). However these methods do not 
enable the simultaneous quantitation of highly hydrophilic metabolite PES as well as PE in 
the in vitro system like LS180 human intestinal cell model, recombinant enzymes and human 
intestinal cytosol. Moreover the LLOQ of PE reported by Dousa et.al was 0.23 mg/L and a 
run time of 3.6 minutes and this method was employed on commercial samples of PE in 
pharmaceutical formulations (15). The method does not enable us to detect PES. The 
observed LLOQ for our method for PE and PES was 0.39 μg/L and 0.062 μg/L respectively 
with a run time of 6.0 minutes. Due to zwitterionic and hydrophilic character of PES, its 
retention on RP-HPLC column was very poor. Also LC-MS/MS technique could not be used 
due to matrix effects and unreliable chromatography. We have developed and validated a 
hydrophilic interaction liquid chromatography (HILIC) method for the direct detection of 
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phenylephrine 3-O-sulfate (PES) and simultaneous detection of phenylephrine (PE) to study 
the enzyme kinetics and metabolism of PE to enable approaches to reduce the presystemic 
metabolism of PE. This is the first method which facilitates direct detection of PES and also 
simultaneous detection of PE using a zwitterionic HILIC column with improved sensitivity in 
a single short run.  The intensity of PE and PES in HILIC chromatography was 2-fold higher 
as compared to RP-HPLC and the observed LLOQ for PES was 62.5 nM. The method was 
fully validated for the determination of PE and PES in LS180 human intestinal cell model. 
Furthermore, the method was adapted for use with recombinant enzymes and human 
intestinal cytosol (HIC). HILIC chromatography involves hydrophilic partitioning which 
incorporated the use of a liquid-liquid extraction technique for sample preparation using 
50%w/v dextrose. Development of the HILIC assay method was one of the most challenging 
part of the research project. Validation of the HILIC assay method as per the US-FDA 
guidelines confirmed that the method was specific, linear, precise, accurate, and stable over 
the concentration range of analytes tested.  
PE has poor oral bioavailability due to its presystemic metabolism in the intestinal gut wall 
majorly through Phase II conjugation that is sulfation pathway. Hence in order to improve the 
bioavailability of PE and to improve its efficacy, a strategy of using phenolic compounds 
from FDA “GRAS” /dietary compounds list which are generally regarded as safe to inhibit 
metabolism of PE were tested. The validated HILIC assay method was employed to 
determine IC50 values using these GRAS compounds using LS180 cell model. Optimization 
studies with the LS180 cell model suggested that the formation of PES is linear with respect 
to substrate concentration up to 8 hours and the substrate concentration of 50 µM which was 
much below the Km value (149 µM). Saturation of formation of PES at higher substrate 
concentrations indicated sulfation is a minor pathway at those concentrations. Resveratrol, 
eugenol, isoeugenol and zingerone showed good inhibitory activity towards PES formation in 
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this model. It also helped in screening of inhibitors and also to estimate the concentration of 
inhibitors to be used for further studies. Studies with LS180 cell model showed SULT1A3-
like activity, where 1-naphthol and PE were sulfated which are two known SULT1A3 
substrates (9, 26)  DPBS buffer used for the study did not include sulfate and hence the 
system was falling short of PAPS which gave an apparent Hill co-efficient (0.69 ± 0.06) 
showing apparent negative cooperativity. Also the extraction process was time consuming 
and tedious. The LS180 cell culture model is a human colon adenocarcinoma cell line, which 
does not exactly represent small intestine, where most of the drug absorption occurs. The 
enzymatic activities are usually lower than the small intestine (29). These were the major 
limitations of the LS180 cell studies.  
These cell-based assays showed presence of an unknown metabolite apart from PES. The 
intensity of this unknown metabolite peak was proportional with respect to the substrate 
concentration and it eluted much earlier as compared to PES on the HILIC column. This 
provided a basis that it could be an MAO metabolite as they more lipophilic as compared to 
sulfate metabolite (PES). In order to confirm this hypothesis, the formation of this unknown 
metabolite was observed in presence of various MAO inhibitors. The formation of this 
unknown metabolite was significantly inhibited in presence of clorgyline (MAO-A inhibitor) 
and pargyline (MAO inhibitor used non-selectively at 10µM), which indicated that the 
unknown metabolite is majorly an MAO-A metabolite. Also in presence of resveratrol and 
pterostilbene the intensity of the unknown metabolite was significantly greater than the 
control, which suggests that there might be a shift to MAO pathway due to inhibition of 
sulfation pathway through resveratrol and pterostilbene. This still needs to be confirmed. 
Although it could be inferred that the unknown metabolite was an MAO-A metabolite, 
identification of this metabolite was not possible. This can be due to the formation of various 
combination products between 3-hydroxy mandelaldehyde and amines to form Schiff bases. 
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Future studies may involve to elucidating the structure of this metabolite, study the enzyme 
kinetic parameters of this pathway and its contribution towards PE metabolism in this LS180 
cell model. Also the relative contribution of the sulfation and MAO pathways could not be 
quantitatively determined due to lack of information of the unknown MAO metabolite.  
Kinetic studies on sulfation inhibition with phenolic GRAS or dietary compounds using 
recombinant SULT1A3 and human intestinal cytosol (HIC) were done in order to estimate 
the Ki values of the GRAS compound with the maximum inhibitory capacity towards 
sulfation of PE. The optimization experiments done with SULT1A3 suggested that the 
formation of PES was linear up to 30 minutes at 5 µM and 200 µM PE and the protein 
concentration was optimized to 1 µg/mL. The PES formation saturation study with SULT1A3 
using a wide range of substrate concentrations provided a valuable information of Km and 
Vmax values. These optimization experiments provided a basis for the incubation time, protein 
and substrate concentrations to be used in order to screen the inhibitors using SULT1A3. 
When the inhibitors were screened using SULT1A3, maximum inhibition was obtained using 
resveratrol. The Km value obtained with the LS180 cell model was almost 2.5 times higher as 
compared to Km value obtained with SULT1A3. 
Further studies involved to determine the mechanism of inhibition for the selected inhibitor 
using HIC. HIC depicted a picture which was closer to what would happen at the 
physiological level. The optimization experiments with HIC suggested that the formation of 
PES was linear up to 30 minutes at 5 µM and 200 µM PE and the protein concentration was 
optimized to 250 µg/mL. The Km value obtained using PES formation saturation study with 
HIC 73 µM (95% CI: 66 to 79) was not statistically different as compared to the Km value of 
65 µM (95% CI: 58 to 71) obtained using SULT1A3. The Vmax value obtained using 
SULT1A3 was above 200-fold higher as compared to that obtained using HIC. This was due 
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to the increased expression of SULT1A3 in the recombinant overexpression system as 
compared to HIC, as HIC has presence of many other proteins too. In order to determine the 
mechanism of inhibition, preliminary study was done to estimate the IC50 value of resveratrol 
using HIC. This study provided a fair idea of the concentration range of the inhibitor to be 
used for the mechanism of inhibition study. The limitation to this study was that the 
concentration range used for inhibitor was not broad enough at the higher end and hence 
complete inhibition of PES formation was not observed. The broad concentration range of the 
inhibitor would have provided a better estimate of the IC50 value and hence the Ki for 
resveratrol.  
For the mechanism of inhibition study, substrate concentration (3.12 µM – 200 µM) and 
inhibitor concentration range (0 µM – 21 µM) was used. When different models were 
compared the non-competitive inhibition model gave the best fit as compared to others. The 
Km and Vmax values obtained using the non-competitive inhibition model were comparable 
with those obtained from the PES formation saturation study using HIC without any inhibitor. 
This provided a stronger basis for the non-competitive inhibition model. The goodness of fit, 
the higher R
2 
value and 95% CI intervals for the parameter estimates were obtained for non-
competitive inhibition model. Also the published literature has shown that the sulfation of 
17α-ethinyloestradiol was inhibited by vanillin. Vanillin was found to inhibit 50% of liver 
17α-ethinyloestradiol sulfotransferase activity (IC50) at a concentration of approximately 1.3 
μM and the mode of inhibition was non-competitive (25). The major drawback of this study 
was that the substrate concentration range used was not broad enough and it is clearly seen in 
the semi-log plot were PES formation is not saturated at 200 µM PE. A broader substrate 
concentration range would have provided a better confidence over the parameter estimates. 
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Future studies needs to be done in order to determine the amount of PAP and resveratrol in 
the reaction mixture at the end of 30 minutes. This would confirm whether the non-
competitive inhibition is due to the product inhibition caused due to PAP. The permeability 
of these GRAS/dietary compounds across the intestinal cell membrane also needs to be 
studied. The Ki value obtained for resveratrol using all the four models were between 3-10 
µM. In order to clinically investigate this approach, maximum dose which can be given 
safely should be studied. Also we need to know the concentration of resveratrol in the cytosol 
of the intestinal cells. The concentration of inhibitor would be chosen upon its capacity to 
inhibit SULT1A3, maximum dose of the inhibitor that can be used in vivo and toxicity of the 
inhibitor itself. 
All in all, HILIC assay method developed provided a quick and reliable way for direct 
detection of PE, PES and the unknown MAO metabolite. The developed method could be 
tried on the in vivo detection of PE and the metabolites. The strategy of using GRAS or 
dietary compounds gave promising results in vitro but the clinical relevance of this approach 
still needs to be reconfirmed. By using the appropriate scaling factors (amount of SULT1A3 
in the gut, weight of the intestine and fraction unbound for PE) would help in determining the 
intrinsic clearance in vivo through the sulfation pathway. The studies done in vitro provided 
data to be used to predict in vivo intrinsic clearance through the sulfation pathway. The future 
goal is to develop a product containing PE in combination with one or more GRAS 
compounds in order to reduce its first pass metabolism in the gut through sulfation and in turn 
increase the oral bioavailability of PE. 
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